3-溴-2-甲氧基苯甲酸甲酯 | 260806-90-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-2-甲氧基苯甲酸甲酯
• 英文名称: methyl 3-bromo-2-methoxybenzoate
• CAS: 260806-90-4
• 化学式: C₉H₉BrO₃
• 分子量: 245.073
• InChiKey: YMRGVTKIFLNUFC-UHFFFAOYSA-N

物化性质

• 沸点：
  289.4±20.0 °C(Predicted)
• 密度：
  1.462±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下，请保持干燥密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: methyl 3-bromo-2-methoxybenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: methyl 3-bromo-2-methoxybenzoate
CAS number: 260806-90-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9BrO3
Molecular weight: 245.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴-2-甲氧基苯甲酸甲酯 在 氢氧化钾 、 氯化亚砜 、 magnesium 作用下， 以 甲醇 、 水 为溶剂， 反应 17.5h， 生成 (3-Brom-2-methoxyphenyl)-3-(1,3-dioxan-2-yl)-1-propanon
  参考文献：
  名称：

  Laatsch, Hartmut; Pudleiner, Heinz, Liebigs Annalen der Chemie, 1989, p. 863 - 882

  摘要：

  DOI：
• 作为产物：
  描述：

  3-溴-2-甲氧基苯甲酸 在 硫酸 作用下， 以 甲醇 为溶剂， 以92%的产率得到3-溴-2-甲氧基苯甲酸甲酯
  参考文献：
  名称：

  [EN] ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS
  [FR] COMPOSÉS HÉTÉROARYLE SUBSTITUÉS PAR ARYLE ET HÉTÉROARYLE-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE TYK2

  摘要：

  公开了一种化合物，其为新颖的羧酰胺取代化合物，化学式为（I）；以及其制备方法，包含它们的药物组成物和它们作为酪氨酸激酶2（Tyk2）抑制剂在治疗中的用途。

  公开号：

  WO2021204626A1

文献信息

• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• Synthesis and pharmacological evaluation of new biphenylic derivatives as CB 2 receptor ligands
  作者：Simone Bertini、Andrea Chicca、Chiara Arena、Stefano Chicca、Giuseppe Saccomanni、Jürg Gertsch、Clementina Manera、Marco Macchia

  DOI：10.1016/j.ejmech.2016.03.072

  日期：2016.6

  feasible strategy to develop new drugs for the treatment of diseases like neuropathic pain, chronic inflammation, neurodegenerative disorders and cancer. Such drugs are devoid of the undesired central side effects that are typically mediated by the CB1 receptor. In this work we synthesized 18 biphenylic carboxamides as new CB2-selective ligands and evaluated their pharmacological profiles. The functional

  靶向2型大麻素受体（CB 2）被认为是开发用于治疗诸如神经性疼痛，慢性炎症，神经退行性疾病和癌症等疾病的新药的可行策略。此类药物没有通常由CB 1受体介导的不良中心副作用。在这项工作中，我们合成了18种联苯羧酰胺作为新的CB 2选择性配体并评估其药理学特征。这些化合物的功能活性受到联苯支架4'和5位上取代基的性质的强烈影响。位置5似乎独立于位置4'中的取代基负责激动剂或反向激动剂的行为，除了甲氧基基团将完全激动剂和反向激动剂都转变为中性拮抗剂。这项研究提供了一个新颖的完整的CB 2功能调节剂工具箱，该工具箱来自相同的化学支架。此类探针可用于研究CB 2受体在细胞分析中的生物学作用。
• [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS<br/>[FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2021239117A1

  公开（公告）日：2021-12-02

  Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。
• Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands
  作者：Simone Bertini、Teija Parkkari、Juha R. Savinainen、Chiara Arena、Giuseppe Saccomanni、Simone Saguto、Alessia Ligresti、Marco Allarà、Agostino Bruno、Luciana Marinelli、Vincenzo Di Marzo、Ettore Novellino、Clementina Manera、Marco Macchia

  DOI：10.1016/j.ejmech.2014.11.066

  日期：2015.1

  depth the role of the CB2 receptor, because they lack the ability to counteract its “constitutive” activity. Here we describe the synthesis and biological activity of a series of biphenylic carboxamides as a new class of CB2 receptor selective ligands. In binding assays, one of these compounds showed good CB2 receptor affinity and selectivity (Ki = 11.48 nM; Selectivity Index = 130). Furthermore, in functional

  CB2受体是对多种疾病（包括疼痛，炎症，神经退行性疾病，癌症和骨质疏松症）越来越重要的治疗目标。尽管已经开发出几种具有CB2选择性激动剂或反向激动剂特性的化合物，但实际上只有很少的CB2受体选择性中性拮抗剂是已知的。这种类型的化合物可用于更深入地研究CB2受体的作用，因为它们缺乏抵消其“组成”活性的能力。在这里，我们描述了一系列联苯羧酰胺作为一类新的CB2受体选择性配体的合成和生物活性。在结合测定中，这些化合物之一显示出良好的CB2受体亲和力和选择性（K i = 11.48 nM；选择性指数= 130）。此外，在功能测定中，相同的化合物显示出与CB2受体选择性中性拮抗剂非常相似的药理作用。这些结果为包括结构优化在内的进一步发展铺平了道路，目的是获得具有这种独特特征的更有效的CB2受体配体。
• ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS
  申请人：Chow Ken

  公开号：US20080194650A1

  公开（公告）日：2008-08-14

  The invention provides well-defined aryl fluoroethyl ureas that are useful as selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of alpha 2 adrenergic receptors.

  本发明提供明确定义的芳基氟代乙基脲，用作选择性的α2肾上腺素能激动剂。因此，所述化合物可用于治疗与α2肾上腺素能受体调节相关的一系列疾病。